Physician profile
Robert Reilly
NPI 1124178819
$16,312.12
in general payments reported to CMS, 2019-2025
76 companies · $3,377 in 2025
The $3,377 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,268 · 2020: $490 · 2021: $1,006 · 2022: $2,710 · 2023: $3,102 · 2024: $3,359 · 2025: $3,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,722 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,722.39 |
| Education | $115.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,263.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $899.58 | 2019-2025 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals Lp | $850.76 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $781.80 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $757.84 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $754.23 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Pfizer INC. | $731.66 | 2019-2025 | |
| Daiichi Sankyo INC. | $632.36 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Genentech USA, INC. | $602.77 | 2019-2025 | Venclexta, Polivy, Phesgo |
| Abbvie INC. | $562.10 | 2019-2025 | |
| Eisai INC. | $527.55 | 2019-2025 | |
| Genmab U.S., INC. | $417.16 | 2021-2025 | Tivdak, Epkinly |
| Astellas Pharma US INC | $413.77 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Amgen INC. | $412.57 | 2019-2023 | Kyprolis, Blincyto, Vectibix |
| Celgene Corporation | $393.29 | 2019-2025 | Reblozyl, Pomalyst |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $366.17 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $364.35 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Genzyme Corporation | $340.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $334.64 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Lilly USA, LLC | $296.14 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $293.53 | 2019-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $240.73 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $235.90 | 2019-2025 | Nerlynx |
| Regeneron Healthcare Solutions, INC. | $208.33 | 2019-2025 | Libtayo |
| Kite Pharma, INC. | $199.63 | 2022-2025 | Yescarta |
| Stemline Therapeutics INC. | $186.06 | 2023-2025 | Orserdu |
| Array Biopharma INC | $181.18 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Tersera Therapeutics LLC | $172.21 | 2022-2024 | Zoladex |
| Emd Serono, INC. | $172.08 | 2019-2025 | Bavencio, Tepmetko |
| Seagen INC. | $157.56 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Morphosys, US INC. | $152.09 | 2021-2024 | Monjuvi |
| Sobi, INC | $143.54 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $132.99 | 2021-2024 | Monoferric |
| Acrotech Biopharma INC. | $121.20 | 2021-2025 | Beleodaq |
| Mirati Therapeutics, INC. | $111.30 | 2023-2024 | Krazati |
| Exelixis INC. | $107.52 | 2022-2024 | Cabometyx |
| Karyopharm Therapeutics INC. | $98.97 | 2020-2024 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.58 | 2019-2025 | Gilotrif |
| Myovant Sciences INC. | $81.46 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $81.25 | 2019-2025 | |
| Tesaro, INC. | $77.29 | 2019 | |
| Beone Medicines USA, INC. | $72.96 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $72.73 | 2024-2025 | Onivyde, Somatuline Depot |
| Recordati_rare_diseases_inc. | $71.55 | 2024-2025 | Sylvant |
| Taiho Oncology, INC. | $71.20 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $68.02 | 2019-2023 | Xarelto |
| Mylan Institutional INC. | $67.49 | 2022-2023 | Fulphila, Ogivri |
| Foundation Medicine, INC. | $67.39 | 2023 | Foundationone Cdx |
| Beigene USA, INC. | $66.20 | 2024-2025 | Tevimbra, Brukinsa |
| Apellis Pharmaceuticals, INC. | $66.13 | 2023-2024 | Empaveli |
| Alexion Pharmaceuticals, INC. | $65.91 | 2023-2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $57.72 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Deciphera Pharmaceuticals INC. | $49.67 | 2021-2025 | Qinlock, Tgct |
| Myriad Genetic Laboratories, INC. | $46.25 | 2024 | Myrisk |
| Kyowa Kirin, INC. | $45.47 | 2024-2025 | Poteligeo |
| Pharmaessentia USA Corporation | $41.24 | 2022-2023 | Besremi |
| Aveo Pharmaceuticals, INC. | $38.46 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $37.38 | 2019 | |
| Fortovia Therapeutics, INC. | $30.73 | 2019-2020 | |
| Blueprint Medicines Corporation | $29.00 | 2022 | |
| Immunogen, INC. | $28.80 | 2023 | Elahere |
| Sumitomo Pharma America, INC. | $27.40 | 2023 | Orgovyx |
| G1 Therapeutics, INC. | $24.04 | 2023 | Cosela |
| Heron Therapeutics, INC. | $18.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.87 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.73 | 2025 | Givlaari |
| Amag Pharmaceuticals, INC. | $17.08 | 2019 | |
| Dova Pharmaceuticals | $16.99 | 2020 | |
| Clovis Oncology, INC. | $16.22 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.79 | 2022 | |
| Servier Pharmaceuticals LLC | $15.71 | 2024 | |
| Azurity Pharmaceuticals, INC. | $15.33 | 2025 | Danziten |
| Secura Bio, INC. | $15.02 | 2024 | Copiktra |
| Spectrum Pharmaceuticals INC. | $14.85 | 2025 | Rolvedon |
| Caris Mpi, INC. | $14.82 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $14.08 | 2024 |
Drugs and devices associated with these payments
Enhertu $645Keytruda $422Kisqali $355Lenvima $325Epkinly $292Jakafi $289Monjuvi $268Reblozyl $258Imbruvica $250Venclexta $245Tivdak $213Verzenio $212Nubeqa $193Libtayo $190Orserdu $186Calquence $184Imfinzi $174Fabhalta $172Opdualag $166Welireg $163Xtandi $159Jemperli $157Zejula $157Stivarga $149Pemazyre $148Lynparza $143Jaypirca $143Zoladex $143Ninlaro $132Niktimvo $128Opdivo $124Mektovi $121Braftovi $121Yescarta $116Brukinsa $116Xofigo $115Elahere $114Krazati $111Darzalex $108Erleada $101Nerlynx $99.13Piqray $92.90Cabometyx $90.78Lorbrena $87.85Xpovio $82.41Beleodaq $81.18Rybrevant $80.45Ibrance $79.86Adcetris $79.37Padcev $78.55Vitrakvi $77.47Retevmo $75.37Ojjaara $75.20Alunbrig $75.10Onivyde $72.73Somatuline Depot $72.73Sylvant $71.55Mekinist $67.65Talvey $67.52Monoferric $67.32Trodelvy $67.32Empaveli $66.13Ultomiris $65.91Elrexfio $64.51Vonjo $63.24Tecvayli $60.16Fruzaqla $59.63Comirnaty $59.07Polivy $53.05Besponsa $51.64Bosulif $51.64Injectafer $51.49Datroway $51.45Phesgo $50.65Lupron Depot $50.13Jevtana $49.17Tevimbra $46.92Xalkori $46.67Myrisk $46.25Poteligeo $45.47Doptelet $44.02Carvykti $42.18Pluvicto $40.71Zepzelca $40.11Tavalisse $39.64Rezlidhia $39.64Lutathera $38.80Fotivda $38.46Paxlovid $36.89Tukysa $36.20Tecentriq $35.55Sarclisa $35.48Blincyto $35.25Kyprolis $35.25Enjaymo $33.91Qinlock $33.00Vyloy $31.18Xarelto $28.05Orgovyx $27.40Ayvakit $24.97
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.